Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.
Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC).
Historically, single-agent checkpoint inhibitors have not elicited significant survival benefits in patients with mCRPC, explains Graff. However, higher response rates have been noted with combination therapies.
The phase 1b/2 KEYNOTE-365 trial evaluated the efficacy of pembrolizumab (Keytruda) plus the PARP inhibitor olaparib (Lynparza), and pembrolizumab plus docetaxel and prednisone, says Graff.
Additional combinations of interest include PD-1 inhibitors plus CLTA-4 inhibitors, concludes Graff.